Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India
- PMID: 11796356
- PMCID: PMC127030
- DOI: 10.1128/AAC.46.2.443-450.2002
Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India
Abstract
The World Health Organization has identified India as a major hot-spot region for Mycobacterium tuberculosis infection. We have characterized the sequences of the loci associated with multidrug resistance in 126 clinical isolates of M. tuberculosis from India to identify the respective mutations. The loci selected were rpoB (rifampin), katG and the ribosomal binding site of inhA (isoniazid), gyrA and gyrB (ofloxacin), and rpsL and rrs (streptomycin). We found known as well as novel mutations at these loci. Few of the mutations at the rpoB locus could be correlated with the drug resistance levels exhibited by the M. tuberculosis isolates and occurred with frequencies different from those reported earlier. Missense mutations at codons 526 to 531 seemed to be crucial in conferring a high degree of resistance to rifampin. We identified a common Arg463Leu substitution in the katG locus and certain novel insertions and deletions. Mutations were also mapped in the ribosomal binding site of the inhA gene. A Ser95Thr substitution in the gyrA locus was the most common mutation observed in ofloxacin-resistant isolates. A few isolates showed other mutations in this locus. Seven streptomycin-resistant isolates had a silent mutation at the lysine residue at position 121. While certain mutations are widely present, pointing to the magnitude of the polymorphisms at these loci, others are not common, suggesting diversity in the multidrug-resistant M. tuberculosis strains prevalent in this region. Our results additionally have implications for the development of methods for multidrug resistance detection and are also relevant in the shaping of future clinical treatment regimens and drug design strategies.
Figures



Similar articles
-
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea.Diagn Microbiol Infect Dis. 2013 Jun;76(2):187-96. doi: 10.1016/j.diagmicrobio.2013.02.035. Epub 2013 Apr 2. Diagn Microbiol Infect Dis. 2013. PMID: 23561273
-
Molecular mechanisms of drug resistance in Mycobacterium tuberculosis clinical isolates.Chin Med J (Engl). 1999 Jun;112(6):524-8. Chin Med J (Engl). 1999. PMID: 11601331
-
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India.Antimicrob Agents Chemother. 2010 Nov;54(11):4789-93. doi: 10.1128/AAC.00661-10. Epub 2010 Aug 16. Antimicrob Agents Chemother. 2010. PMID: 20713679 Free PMC article.
-
[Multidrug-resistant tuberculosis. 2. Mechanisms of drug-resistance in Mycobacterium tuberculosis--genetic mechanisms of drug-resistance].Kekkaku. 1998 Nov;73(11):657-63. Kekkaku. 1998. PMID: 9866928 Review. Japanese.
-
Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update.Tuber Lung Dis. 1998;79(1):3-29. doi: 10.1054/tuld.1998.0002. Tuber Lung Dis. 1998. PMID: 10645439 Review.
Cited by
-
Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis.Indian J Med Res. 2011 Nov;134(5):696-703. doi: 10.4103/0971-5916.90999. Indian J Med Res. 2011. PMID: 22199110 Free PMC article.
-
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes.Antimicrob Agents Chemother. 2006 Jan;50(1):104-12. doi: 10.1128/AAC.50.1.104-112.2006. Antimicrob Agents Chemother. 2006. PMID: 16377674 Free PMC article.
-
Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait.Ann Clin Microbiol Antimicrob. 2009 Jan 15;8:2. doi: 10.1186/1476-0711-8-2. Ann Clin Microbiol Antimicrob. 2009. PMID: 19146672 Free PMC article.
-
Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.Antimicrob Agents Chemother. 2017 Jul 25;61(8):e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug. Antimicrob Agents Chemother. 2017. PMID: 28507117 Free PMC article.
-
Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.PLoS One. 2015 Mar 27;10(3):e0120470. doi: 10.1371/journal.pone.0120470. eCollection 2015. PLoS One. 2015. PMID: 25816236 Free PMC article.
References
-
- Basso, L. A., R. Zheng, J. M. Musser, W. R. Jacobs, Jr., and J. S. Blanchard. 1998. Mechanism of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178:769–775. - PubMed
-
- Bloom, B. R., and J. L. Murray. 1992. Tuberculosis: commentary on a reemergent killer. Science 257:1055–1064. - PubMed
-
- Bottger, E. C. 1994. Resistance to drugs targeting protein synthesis in mycobacteria. Trends Microbiol. 2:416–421. - PubMed
-
- Centers for Disease Control and Prevention. 1993. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. Morb. Mortal. Wkly. Rep. 42(RR-7). - PubMed
-
- Cohn, D. L., F. Bustreo, and M. C. Raviglione. 1997. Drug-resistant tuberculosis: review of the worldwide situation and the W.H.O./IULATD global surveillance project. Clin. Infect. Dis. 24:(Suppl. 1)S121–S130. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources